# CEL Sci Corp: Form 10-Q for the period ended Jun 30, 2015

- Company: [CEL Sci Corp](/companies/cvm.md) (CIK 725363)
- Form: 10-Q
- Filed: 2015-08-07
- Accepted by EDGAR: Aug 7, 2015, 20:32 ET
- Period: 2015-06-30
- Accession: 0001354488-15-003627
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/725363/000135448815003627/cvm_10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/725363/000135448815003627/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2015-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Research and development | 3 months, 2015-04-01 to 2015-06-30 | $5.7m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2014-10-01 to 2015-06-30 | $15.6m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2015-04-01 to 2015-06-30 | −$8.2m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2014-10-01 to 2015-06-30 | −$26.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2015-04-01 to 2015-06-30 | $41.6k | us-gaap:InterestExpense |
| Interest expense | 9 months, 2014-10-01 to 2015-06-30 | $124.9k | us-gaap:InterestExpense |
| Net income | 3 months, 2015-04-01 to 2015-06-30 | −$4.4m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2014-10-01 to 2015-06-30 | −$24.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2015-04-01 to 2015-06-30 | −$0.06 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2014-10-01 to 2015-06-30 | −$0.32 | us-gaap:EarningsPerShareBasicAndDiluted |
| Basic EPS | 3 months, 2015-04-01 to 2015-06-30 | −$0.05 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2015-04-01 to 2015-06-30 | 85,134,107 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2014-10-01 to 2015-06-30 | −$18.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2014-10-01 to 2015-06-30 | $56.6k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2015-06-30 | $11.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2015-06-30 | $14.7m | us-gaap:AssetsCurrent |
| Total assets | at 2015-06-30 | $21.5m | us-gaap:Assets |
| Current liabilities | at 2015-06-30 | $5.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2015-06-30 | $17.6m | us-gaap:Liabilities |
| Shareholders' equity | at 2015-06-30 | $3.9m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 14,879 characters.

#### Liquidity and Capital Resources

The Company’s lead investigational therapy, Multikine® (Leukocyte Interleukin, Injection), is currently being tested in a Phase 3 clinical trial in advanced primary head and neck cancer. Multikine has been cleared by the regulators in eighteen countries around the world, including the U.S. FDA. Multikine is also being used in a Phase 1 study at the Naval Medical Center, San Diego under a CRADA with the U.S. Navy in HIV/HPV co-infected men and women with peri-anal warts.

Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this report as Multikine. Multikine is the trademark that the Company has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with the Company’s future anticipated regulatory submission for approval. Multikine has not been licensed or approved by the FDA or any other regulatory agency. Neither has its safety or efficacy been established for any use.

The Company also owns and is developing a pre-clinical technology called LEAPS (Ligand Epitope Antigen Presentation System).

All of the Company’s projects are under development. As a result, the Company cannot predict when it will be able to generate any revenue from the sale of any of its products.

Since inception, the Company has financed its operations through the sale of equity securities, convertible notes, loans and certain research grants. The Company’s expenses will likely exceed its revenues as it continues the development of Multikine and brings other drug candidates into clinical trials. Until such time as the Company becomes profitable, any or all of these financing vehicles or others may be utilized to assist the Company’s capital requirements.

Capital raised by the Company has been expended primarily for patent applications, debt repayment, research and development, administrative costs, and the construction of the Company’s laboratory facilities. The Company does not anticipate realizing significant revenues until it enters into licensing arrangements regarding its technology and know-how or until it receives regulatory approval to sell its products (which could take a number of years). As a result the Company has been dependent upon the proceeds from the sale of its securities to meet all of its liquidity and capital requirements and anticipates having to do so in the future.

The Company will be required to raise additional capital or find additional long-term financing in order to continue with its research efforts. The ability of the Company to complete the necessary clinical trials and obtain FDA approval for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure. The Company believes that, counting its cash on hand and access to the capital markets established over the years, it will have enough capital to support its operations through year end.

The Company estimates the total remaining cash cost of the Phase 3 trial, with the exception of the parts that will be paid by its licensees, Teva Pharmaceuticals and Orient Europharma, to be approximately $22.1 million. This is in addition to approximately $22.5 million which has been paid as of June 30, 2015. This estimate is based on the information currently available in the Company’s contracts with the Clinical Research Organization responsible for managing the Phase 3 trial. This number can be affected by the speed of enrollment, foreign currency exchange rates and many other factors, some of which cannot be foreseen today. It is therefore possible that the cost of the Phase 3 trial will be higher than currently estimated.

In April 2013, the Company announced that it has replaced the CRO running its Phase 3 clinical trial. This was necessary since the patient enrollment in the study dropped off substantially following a takeover of the CRO which caused most of the members of the CRO’s study team to leave the CRO. The Company announced that it has hired two CRO’s who will manage the global Phase 3 study; Aptiv Solutions and Ergomed who are both international leaders in managing oncology trials. Both CRO’s have helped the Company expand the trial to over -80 clinical sites globally. As of June 30, 2015, the study has enrolled 488 patients. The centers where the study is being conducted include two centers in Israel where the Company’s partner Teva Pharmaceuticals has the marketing rights, and nine centers in Taiwan where the Company’s partner Orient Europhama has the marketing rights. The Company expects to see a further increase in the number of patients enrolled in the study at an accelerating pace as treating physicians gain experience with Multikine.

Although the Company is aiming to enroll 880 patients, the Phase 3 study requires a total of 784 evaluable patients. The Company is estimating that such enrollment will be completed in March 2016. Following full enrollment of the study, the Company has to wait for 298 events (deaths) in the two comparator arms combined to determine if the Company has met the primary endpoint, which is a 10% increase in overall survival in the Multikine arm over the comparator arm. The Company estimates that the final data read-out of this Phase 3 clinical trial could occur by the second half of 2017 based on our enrollment projections and estimated survival curves provided in scientific literature.

Under a co-development agreement, Ergomed will contribute up to $10 million towards the study where it will perform clinical services in exchange for a single digit percentage of milestone and royalty payments, up to a specified maximum amount, only from sales for head and neck cancer. Ergomed, a privately-held firm headquartered in Europe with global operations, has entered into numerous similar co-development agreements, including one with Genzyme (purchased by Sanofi in 2011 for over $20 billion). Ergomed will be responsible for the majority of the new patient enrollment.

During the nine months ended June 30, 2015, the Company’s cash increased by approximately $2,717,000. Significant components of this increase include net proceeds from the sale of the Company’s stock of approximately $21,279,000 offset by net cash used to fund the Company’s regular operations, including its on-going Phase 3 clinical trial, of approximately $18,490,000, purchases of equipment of approximately $57,000, patent expenditures of approximately $9,000 and payments on capital leases of approximately $6,000. During the nine months ended June 30, 2014, the Company’s cash increased by approximately $14,244,000. Significant components of this increase include net proceeds from the sale of the Company’s stock of approximately $28,429,000 and proceeds from the exercise of warrants of approximately $3,118,000 offset by net cash used to fund the Company’s regular operations, including its on-going Phase 3 clinical trial, of approximately $17,197,000, purchases of equipment of approximately $67,000, capitalized patent expenditures of approximately $33,000 and payments on the capital lease of approximately $6,000.

On May 28, 2015, the Company closed an underwritten public offering of 20,253,164 shares of common stock and 20,253,164 Series V warrants to purchase shares of common stock. The common stock and Series V warrants were sold at a combined per unit price of $0.79 for net proceeds of approximately $14.7 million, net of underwriting discounts and commissions and offering expenses. The Series V warrants are immediately exercisable at a price of $0.79 and expire on May 28, 2020.

On October 24, 2014, the Company closed an underwritten public offering of 7,894,737 shares of common stock and 1,973,684 warrants to purchase shares of common stock. For every four shares of common stock sold, investors in this offering were issued a warrant to purchase one share of common stock. The common stock and warrants were sold at a combined price of $0.76 for net proceeds of approximately $5,550,000, net of underwriting discounts and commissions. The warrants were immediately exercisable, expire October 11, 2018 and have an exercise price of $1.25.

Additionally, on October 21, 2014, the Company sold 1,320,000 shares of the Company’s common stock, as well as warrants to purchase an additional 330,000 shares of common stock. For every four shares sold, the Company issued to investors in this offering one warrant. The shares of common stock and warrants are being sold at a combined price of $0.76 per share with net proceeds from the offering of approximately $941,000, net of commissions. The common stock and warrants will separate immediately. The warrants were immediately exercisable, expire October 11, 2018 and have an exercise price of $1.25.

The Company incurred an additional $85,335 in offering costs related to the October 2014 offerings which were charged to additional paid in capital and netted against the cash proceeds.

As of June 30, 2015, the Company had a net tangible book value of $3,625,917, or $0.03 per share of common stock, based on 112,027,058 shares of common stock outstanding as of that date.

#### Results of Operations and Financial Condition

During the nine and three months ended June 30, 2015, grant and other income increased by approximately $527,000 and $373,000 compared to the nine and three months ended June 30, 2014. The increase is primarily due to the timing of drug shipments to supply the Company’s partner in Taiwan and the grant income earned by the Company’s Small Business Innovation Research (SBIR) grant during the nine and three months ended June 30, 2015 compared to June 30, 2014.

During the nine and three months ended June 30, 2015, research and development expenses increased by approximately $2,956,000 and $1,239,000 compared to the nine and three months ended June 30, 2014.

During the nine and three months ended June 30, 2015, general and administrative expenses increased by approximately $4,476,000 and $449,000 compared to the nine and three months ended June 30, 2014. Major components of the increase include approximately $3,237,000 and $194,000, respectively, during the nine and three months ended June 30, 2015, in employee compensation costs related to the issuance of shareholder approved shares of restricted stock during the quarter ended September 30, 2014, and increased legal fees of approximately $1,210,000 and $325,000, respectively over the nine and three month periods primarily relating to the arbitration with the Company’s former CRO, as discussed in Note G – Commitments and Contingencies.

The gain on derivative instruments of approximately $1,809,000 and $4,429,000 for the nine and three months ended June 30, 2015 was the result of the change in fair value of the derivative liabilities during the period. The loss on derivative instruments of approximately $1,054,000 for the nine months ended June 30, 2014 and the gain on derivative instruments of approximately $4,468,000 for the three months ended June 30, 2014 was the result of the change in fair value of the derivative liabilities during the period. This change was caused by fluctuations in the share price of the Company’s common stock.

During the three months ended June 30, 2015, the Company recorded a loss on debt extinguishment of $641,276. This amount was comprised of a $165,943 premium on the note payable held in a related party trust, and an additional expense of $475,333 relating to the modification of Series N warrants also held in the trust. The loss on debt extinguishment resulted from substantive modification of the terms under the note, including an extension of the expiration date and a decrease in the interest rate, and an extension of the expiration date on the warrants.

Interest expense was approximately $125,000 and $42,000, respectively, for the nine and three months ended June 30, 2015 and consisted primarily of interest expense on the loan from the Company’s president. Interest expense was approximately $122,000 and $42,000, respectively, for the nine and three months ended June 30, 2014 and consisted primarily of interest expense on the loan from the Company’s president.

#### Research and Development Expenses

The Company’s research and development efforts involved Multikine and LEAPS. The table below shows the research and development expenses associated with each project.

|  | Nine months ended June 30, 2015 | 2014 | Three months ended June 30, 2015 | 2014 |
| --- | ---: | ---: | ---: | ---: |
| MULTIKINE | $15,207,126 | $12,347,711 | $5,558,700 | $4,361,366 |
| LEAPS | 375,807 | 279,558 | 133,868 | 92,364 |
| TOTAL | $15,582,933 | $12,627,269 | $5,692,568 | $4,453,730 |

Clinical and other studies necessary to obtain regulatory approval of a new drug involve significant costs and require several years to complete. The extent of the Company’s clinical trials and research programs are primarily based upon the amount of capital available to the Company and the extent to which the Company has received regulatory approvals for clinical trials. The inability of the Company to conduct clinical trials or research, whether due to a lack of capital or regulatory approval, will prevent the Company from completing the studies and research required to obtain regulatory approval for any products which the Company is developing. Without regulatory approval, the Company will be unable to sell any of its products. Since all of the Company’s projects are under development, the Company cannot predict when it will be able to generate any revenue from the sale of any of its products.

#### Critical Accounting Estimates and Policies

Management’s discussion and analysis of the Company’s financial condition and results of operations is based on its unaudited condensed financial statements. The preparation of these financial statements is based on the selection of accounting policies and the application of significant accounting estimates, some of which require management to make judgments, estimates and assumptions that affect the amounts reported in the financial statements and notes. The Company believes some of the more critical estimates and policies that affect its financial condition and results of operations are in the areas of operating leases and stock-based compensation. For more information regarding the Company’s critical accounting estimates and policies, see Part II, Item 7 of the Company’s 2014 Annual Report on Form 10-K. The application of these critical accounting policies and estimates has been discussed with the Audit Committee of the Company’s Board of Directors.

## Market risk

As filed, 247 characters.

The Company has a loan from a trust controlled by the Chief Executive Officer that bears interest at 9%. The interest rate was lowered to 9% effective July 7, 2015. The Company does not believe that it has any significant exposures to market risk.

## Controls and procedures

As filed, 1,668 characters.

#### Evaluation of Disclosure Controls and Procedures

Under the direction and with the participation of the Company’s management, including the Company’s Chief Executive and Chief Financial Officer, the Company has conducted an evaluation of the effectiveness of the design and operation of its disclosure controls and procedures as of June 30, 2015. The Company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in its periodic reports with the Securities and Exchange Commission is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and regulations, and that such information is accumulated and communicated to the Company’s management, including its principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. The Company’s disclosure controls and procedures are designed to provide a reasonable level of assurance of reaching its desired disclosure control objectives. Based on the evaluation, the Chief Executive and Chief Financial Officer have concluded that the Company’s disclosure controls and procedures were effective as of June 30, 2015.

#### Changes in Internal Control over Financial Reporting

The Company’s management, with the participation of the Chief Executive and Chief Financial Officer, has evaluated whether any change in the Company’s internal control over financial reporting occurred during the first nine months of fiscal year 2015. There was no change in the Company’s internal control over financial reporting during the nine months ended June 30, 2015.

Filed Aug 7, 2015.
Source: SEC EDGAR, the filing index for accession 0001354488-15-003627. Last ingested by Listed: Oct 24, 2026, 14:55 ET. No prices; not investment advice.
